Cost, adverse effects, reaching a target weight and moving country are all useful reasons to bring to that conversation. A study average is not an instruction to stop, taper or restart treatment yourself.
Contents
Why can hunger and weight return?
Tirzepatide influences appetite and fullness signals. As its effects diminish after treatment ends, hunger or interest in food may change. The experience varies, and feeling hungrier cannot predict how many kilograms an individual will gain.
A smaller body also needs less energy, and biological adaptation after weight loss can make maintenance harder. Eating patterns, sleep, activity, health conditions and other medicines remain relevant. “The stomach expands again” and “poor discipline” are inadequate explanations. NIDDK: maintaining weight loss
A useful plan therefore considers appetite, sustainable eating and ongoing health assessment. It should not depend on recreating the lowest food intake experienced during treatment.
What did SURMOUNT-4 test?
After 36 weeks of tirzepatide, 670 adults with obesity, or overweight with at least one weight-related complication, without diabetes, were randomised to continue treatment or switch to placebo for 52 weeks. Lifestyle support continued. From week 36 to 88, weight rose 14.0% in the placebo group and fell a further 5.5% with continued treatment. The 14.0% uses week-36 body weight as its denominator, not the amount previously lost. SURMOUNT-4
These results describe selected participants who reached randomisation, not everyone starting treatment. Lilly funded the trial. Weight regain should not automatically be interpreted as a failure of willpower.
Participants reaching randomisation had lost an average 20.9% during the initial 36 weeks. From the original baseline to week 88, average weight remained 9.9% lower after switching to placebo, compared with 25.3% lower with continued treatment. Regain therefore did not mean that everyone returned to their original weight. These remain group averages, not an individual forecast.
Read the trial as a timeline
| Stage or result | What happened | Interpretation limit |
|---|---|---|
| Initial 36 weeks | Participants received tirzepatide | Not a comparison of starting medicine versus no treatment from day one |
| Next 52 weeks | 670 participants were randomised to continue or receive placebo | Selected participants had completed the initial phase |
| Placebo-switch group | Mean weight increased 14.0% from week 36 | Not 14% of previously lost weight; individual responses varied |
| Continued-treatment group | Mean weight fell another 5.5% from week 36 | Not a universal treatment target |
| Continuing support | Dietary and activity advice | Not a comparison of disciplined and undisciplined patients |
For arithmetic only, a 14% increase from an 80 kg starting point is 11.2 kg. This illustrates the denominator; it does not predict that an 80 kg person will gain that amount.
How soon will hunger or weight change?
There is no single day that applies to everyone. SURMOUNT-4 followed changes over months and reported its main outcome at the end of the 52-week randomised period. That endpoint is not a first-month forecast and should not be divided into a constant weekly gain.
Appetite, weight and blood glucose do not necessarily change at the same pace. Short-term weight is also affected by fluid, food in the digestive tract and bowel movements. An abrupt change with swelling, breathlessness or other concerning symptoms needs assessment rather than being assumed to be ordinary regain.
Instead of waiting for an arbitrary deadline, agree a baseline and what pattern should prompt contact. Planned monitoring can support earlier reassessment, but cannot guarantee prevention of regain.
Does that mean treatment must be lifelong?
The trial does not determine your personal stopping point or predict who can maintain weight without medication. It also excluded diabetes, so it cannot replace a glucose-management plan for someone receiving tirzepatide for that condition.
Newer research matters too. SURMOUNT-MAINTAIN, published in 2026, examined additional maintenance approaches, including reduced treatment intensity under supervision. It is inaccurate to frame the decision as necessarily keeping the same regimen forever or stopping everything. This research does not establish a do-it-yourself adjustment protocol. SURMOUNT-MAINTAIN
Long-term care does not mean an unchangeable regimen
For some people, ongoing health benefits may support continuing treatment. Others have reasons to reconsider the approach, including adverse effects, new health circumstances or cost. Reaching a target weight does not answer every clinical question, and continuing follow-up does not mean one medicine or regimen must remain unchanged for life.
Ask which benefits need to be maintained, which options fit your health conditions and when the decision will be reviewed. A fixed promise about the number of years of treatment is not an individualised plan.
What should the prescriber discussion cover?
Review why you want a change, health benefits achieved, adverse effects, affordability and whether ongoing care is practical. Explain if appetite changes or gastrointestinal symptoms are making eating difficult. Tell the clinician promptly about pregnancy or plans to become pregnant.
Ask what health goals matter next, who will coordinate care, and what should trigger an earlier review. If you have already stopped and are concerned about regain, contact the prescriber rather than independently returning to an old regimen.
Different situations need different information
| Situation | Bring to the discussion | Avoid assuming |
|---|---|---|
| Target weight reached | Health goals, related conditions and sustainable routines | Every health problem has resolved |
| Troublesome symptoms | Onset, severity and ability to eat and drink | Every adverse effect must be tolerated to maintain weight |
| Cost is unsustainable | Overall cost and realistic financial constraints | Self-directed gaps or changes are the solution |
| Moving country | Travel dates, receiving clinician and records | A new clinic can immediately continue the same plan |
| Already stopped | Last administration date, reason, symptoms and weight trend | The old regimen is automatically appropriate to restart |
Agree on a monitoring plan
Ask which measures are useful for your health history: weight trend, waist measurement, symptoms, blood pressure or blood tests when indicated. A fixed testing package or universal appointment interval is not appropriate for every patient.
Record dates and comparable weighing conditions, alongside appetite, eating, activity, sleep and changes in other medicines. A single reading is a poor basis for a treatment decision. The purpose is to give your clinician context, not to prompt extreme restriction after a higher reading.
Agree what to do if weight is increasing persistently, previous health problems return or eating becomes difficult. Nutrition and function still matter; the goal is not simply to make the scale stop moving.
A useful follow-up record
| Information | Useful detail |
|---|---|
| Weight and date | Comparable weighing conditions plus illness or travel context |
| Hunger and fullness | Timing, change from your usual pattern and impact on meals |
| Eating and daily life | Missed meals, difficult-to-control eating, sleep and realistic activity |
| Other health measures | Returning symptoms or blood pressure/glucose readings specifically requested by the clinician |
| Decisions needed | What is workable, what is difficult and where support is needed |
Not everyone needs continuous glucose monitoring or daily weighing. Tools and frequency should follow clinical need. Tell the team if tracking increases anxiety or disrupts eating so a different approach can be considered.
What if weight has already started returning?
A sustained upward trend is a reason to review the plan, not proof that previous effort was wasted. Bring appetite, eating, symptom and activity information, because weight alone cannot identify the cause of change.
Extreme restriction, supplements marketed to prevent rebound and independently restarting leftover medicine are not substitutes for reassessment. The review may identify nutrition, activity, sleep, medical or treatment factors worth addressing. The response should reflect your current situation rather than another person’s experience online.
Questions after stopping Mounjaro
Does tapering on my own prevent regain?
That cannot be promised. Maintenance research does not validate a universal self-directed stopping schedule that prevents regain. This article provides no taper, spacing or restart protocol.
Will good eating and exercise prevent all regain?
They remain important but do not guarantee it. Both SURMOUNT-4 groups continued receiving lifestyle advice, yet average weight increased after withdrawal. This does not prove every lifestyle programme has the same outcome; it does mean behaviour alone should not be presented as a guarantee.
Does regain mean addiction?
Regain alone is not evidence of addiction. It can reflect the loss of appetite-related treatment effects while factors contributing to obesity persist. If you are worried about relying on medication, discuss benefits, risks and alternatives without treating regain as a moral failure.
Is the situation different if I have diabetes?
Yes. Glucose management and other diabetes medicines need their own review. SURMOUNT-4 excluded diabetes and cannot supply that plan. Stable weight does not establish that glucose control will remain appropriate after a treatment change.
Should I wait until I have regained a lot before asking for help?
No. Agree a contact route when the plan changes, particularly for returning symptoms, difficulty eating or appetite changes that disrupt daily life. Serious symptoms need assessment according to urgency, rather than waiting for the next weight review.
Moving between Thailand and another country
Request a treatment summary with the exact medicine and presentation, reason for treatment, prescribed treatment history, last administration date, adverse effects, other medicines and dated test results. This is information for the receiving clinician, not a self-prescribing checklist.
Identify the receiving clinician, the next appointment and a contact route for problems before a care gap develops. Confirm that the clinic can review records in the language supplied and ask what translation is needed. Do not assume English-speaking care, remote prescribing or a particular product is available.
Agree which records can be sent to which provider and give consent before transfer. Brand names, authorised uses and product presentations can differ between countries; the receiving prescriber needs to check the actual local product information.
Safety takes priority over the weight plan
Severe persistent abdominal pain, inability to keep fluids down or significant dehydration needs urgent assessment. Breathing difficulty or swelling of the face or tongue requires emergency care.
Tell the new clinician about serious allergies, pregnancy and medicines that may cause low blood sugar. The US label lists a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) as contraindications; local labeling must also be reviewed. Previous use does not establish that restarting is appropriate now. Manufacturer information
Use the Mounjaro overview to prepare broader assessment questions, then review your own history with the prescriber. The useful next step is a workable care plan, with no promise that weight regain can always be prevented.